Managing Toxicology for the Future: Improving Predictive Power Through Integrated Technologies (2nd Edition) - Biologics Market Research

Managing Toxicology for the Future: Improving Predictive Power Through Integrated Technologies (2nd Edition)
Published Date: August 2006
Published By: Drug and Market Development Publishing
Page Count: 226
Order Code: R294-214
Price: $4207.50 Online Download
$4207.50 Hard Copy Mail Delivery
From now until December 31, 2006, get this report 15% off! Originally priced at $4,950 for Instant Online Download and Hard Copy Mail Delivery!
During the last three years mergers, the drive to integrate ADME/Tox screening throughout the drug development process is now impacting the issue of late stage candidate attrition. This organizational shift is highlighted in D&MD?s new market analysis report?Managing Toxicology for the Future: Improving Predictive Power Through Integrated Technologies, 2nd Edition. The strategy of moving ADME/Tox-based decision making forward into early compound discovery has been embraced and the report examines the impact this re-structuring is having on Phase II and Phase III drug failures.
This report focuses on the new technologies being employed in toxicology and how they integrate with the discovery and preclinical stages of drug development. Emphasis is placed on the fact that none of the new approaches, including toxicogenomics, toxicoproteomics, in vitro assays or predictive toxicology databases and computational methods, will emerge as a stand-alone solution to drug safety assessment. Each will instead find its place as a component of a larger system of R&D, providing complementary information and supporting conventional methods of animal testing. The state of current and emerging technologies are presented in Chapter 2, along with an assessment of their impact and future role in preclinical research. Chapter 3 analyzes business strategies of companies offering technology platforms in toxicology, pharmaceutical company strategies for technology adoption and outsourcing, the regulatory environment, the business case for pre-competitive development of predictive toxicology, and the impact of pharmacogenomics on drug safety. Chapter 4 examines the impact of adverse drug effects through a case study, and how unanticipated toxicity has resulted in numerous product withdrawals, liability and the reversal of corporate fortunes. Finally, Chapter 5 presents profiles of the top innovative companies and service providers in predictive toxicology and a summary of recent collaborative activity.